JAMA Author Interviews: Covering research in medicine, science,& clinical practice. For physicians, researchers,& clinicians.   /     Intratracheal Budesonide for Extremely Preterm Infants

Description

Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH. Related Content: Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants

Subtitle
Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of...
Duration
08:27
Publishing date
2024-11-11 16:00
Link
https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2024.22763
Contributors
Enclosures
https://traffic.libsyn.com/secure/jamaauthorinterviews/Intratracheal_Budesonide_for_Extremely_Preterm_Infants.mp3?dest-id=90171
audio/mpeg

Shownotes

Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH. Related Content: